Tags : Kevzara

Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for

Shots: The first patient has been treated as a part of the global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The P-II/III clinical program has initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients instantly The study outside the US will assess the safety and efficacy of […]Read More

Sanofi and Regeneron to Restructure its Collaboration for Kevzara (sarilumab)

Shots: Sanofi and Regeneron will simplify their Ab collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement Under the proposed restructuring, Sanofi is expected to get WW rights for Kevzara and (Ex-US) rights for Praluent while Regeneron is expected to get US rights for Praluent. The companies will be responsible to fund development […]Read More